Introduction {#sec1}
============

Breast cancer is the most common malignant tumor in women worldwide \[[@B1]\]. Although docetaxel plays an important role in first-line chemotherapy, drug resistance remains a major obstacle to successful treatment of breast cancer and leads to poor overall survival for patients. The mechanisms of chemoresistance are under intense research, and much attention has been recently paid to the intercellular transfer of tumor-derived exosomes as vehicles for genetic cargo \[[@B2],[@B3]\].

Exosomes are nanosized vesicles of endocytic origin secreted by most cell types and contain a wide variety of active molecules including proteins, lipids, mRNAs, and miRNAs. They could be shuttled into tumor microenvironment and then absorbed by surrounding cancer cells or stromal cells to release their contents, thus serving as mediators for cell-to-cell communication and a potential mechanism for drug resistance \[[@B3]\]. Such phenomenon has been reported in several tumor models, including prostate cancer, glioblastoma, and hepatocellular cancer \[[@B6]\]. By using the ready-established cell lines, our previous study also found that docetaxel-resistant breast cancer cells could spread chemoresistance to sensitive cells by shedding abundant exosomes and that the effects could be partly attributed to the constant transfer of specific miRNAs \[[@B9]\]. Given that genetically engineered exosomes carrying therapeutic mRNAs/proteins still have limitations on clinical application, reducing the formation and shedding of tumor-derived exosomes may be a promising strategy to restore chemosensitivity \[[@B10],[@B11]\].

[d]{.smallcaps} Rhamnose β-hederin (3β-\[(α-[l]{.smallcaps}-arabinopyranosyl)-oxy\] olean-12-en-28-oicacid) (DRβ-H) is an active component isolated from the roots and rhizomes of the Chinese natural plant *Clematis ganpiniana* \[[@B12]\]*.* DRβ-H has been previously reported to inhibit growth and induce apoptosis of breast cancer cells. In the previous work, our group demonstrated that DRβ-H induced mitochondria-mediated apoptosis, regulated expression of Bcl-2 family proteins, and induced apoptosis by inhibiting PI3K/Akt signaling cascade; and activating ERK pathway \[[@B13]\]. Moreover, we confirmed that DRβ-H could inhibit migration and invasion of human breast cancer cell line \[[@B14]\]. However, the relevance of exosomes and contained miRNAs during DRβ-H exposure remains largely unclear.

Since reduced apoptosis, elevated proliferation, and enhanced invasiveness are all hallmarks of drug resistance \[[@B15]\], it implies that DRβ-H could be a novel candidate for the breast cancer treatment, and might reverse chemoresistance. Therefore, the aim of the present study was to evaluate whether DRβ-H acts through regulating the formation and secretion of exosomes and whether this mechanism is responsible for resistance reversal effect.

Materials and methods {#sec2}
=====================

Cell culture and drug preparation {#sec2-1}
---------------------------------

The cell lines used here were drug-sensitive MCF-7 breast cancer cells (MCF-7/S) purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and a docetaxel-resistant variant of MCF-7 cells (MCF-7/Doc) established in our laboratory as recently described. They have been validated earlier by our group as appropriate models for investigating chemotherapy failure *in vitro* \[[@B16]\]. In selected experiments, MCF-7/S expressing GFP (GFP-S) was generated as previously reported \[[@B17]\]. Cells were incubated in an atmosphere of 5% CO~2~ at 37°C and fed with Dulbecco's modified Eagle's medium (DMEM) high glucose (HyClone, U.S.A.), supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. All the cell lines have been confirmed to be free of mycoplasma by using the Mycoplasma Detection Kit-Quick Test (Biotool, U.S.A.). Exosome-depleted FBS was prepared by ultracentrifugation (Avanti J-30I, Beckman Coulter, U.S.A.) at 100000 ***g*** and used for all studies. Protocols of the extraction, purification, and analysis of DRβ-H were described in our recent work \[[@B12]\].

Exosome isolation and characterization {#sec2-2}
--------------------------------------

Exosomes were obtained from the supernatants of MCF-7/S and MCF-7/Doc using a series of centrifugation and ultracentrifugation steps and respectively named as S/exo and D/exo for simplicity. Briefly, the medium was sequentially centrifuged at 300 ***g*** for 10 min, 2000 ***g*** for 15 min, and 12000 ***g*** for 30 min, followed by filtering of the resulting supernatants through a 0.22-μm filter. The filtrates were further ultracentrifuged at 100000 ***g***(Avanti J-30I, Beckman Coulter, U.S.A.) for 2 h, and the exosome pellets were washed in PBS. They were lysed for protein/RNA extraction, labeled for confocal observation, and diluted for incubation assay. In selected experiments, D/exo were treated with 5 U/ml RNase (Ambion, U.S.A.) for 3 h at 37°C, the reaction was ended by 10 U/ml RNase inhibitor (Ambion, U.S.A.) followed by ultracentrifugation. The RNase-treated D/exo were designated as RNase D/exo. The morphology and size of exosomes were observed by TEM as we previously reported \[[@B17]\]. Briefly, exosome pellets were added on parafilm and covered with a 300-mesh copper grid for 45 min. After washing in PBS, the copper grid was fixed in 3% glutaraldehyde, washed, and then contrasted in 2% uranyl acetate. Images were obtained on TEM (JEM-1010, JEOL, Japan) at an acceleration voltage of 80 kV.

Exosome uptake {#sec2-3}
--------------

Exosomes were labeled with the PKH26 Red Fluorescent Cell Linker Kit (Sigma--Aldrich, U.S.A.) in accordance with the manufacturer's instructions. As the negative control, exosomes without PKH26 staining were prepared. Uptake of exosomes was studied on GFP-S (1 × 10^5^ cells per well) seeded in six-well plates. After 3 days of incubation, GFP-S cells were cultured with 80 μg PKH-26 labeled exosomes for 24 h. Then they were visualized by a confocal laser scanning microscope LSM710 (Carl Zeiss, Germany) as reported in our publications \[[@B17]\].

Apoptosis assay {#sec2-4}
---------------

When cells seeded in six-well plates had attached, the supernatants of MCF-7/S were removed and fresh media containing vehicle, S/exo, and D/exo were added. Following a 72-h incubation, cells were treated with 50 nM docetaxel for 24 h. Then, apoptotic rates of MCF-7/S subgroups were evaluated using the Annexin-V-FITC Apoptosis Detection Kit (BD Biosciences, U.S.A.) according to the manufacturer's protocols and analyzed by flow cytometry (BD FACSCalibur, U.S.A.) as previously documented \[[@B13]\]. MCF-7/Doc cells and MCF-7/Doc subgroup incubated with D/exo were maintained under the same conditions as controls.

MTT assay {#sec2-5}
---------

Five groups of cells, namely, MCF-7/S+vehicle, MCF-7/S+S/exo, MCF-7/S+D/exo, MCF-7/Doc, and MCF-7/Doc+D/exo were prepared as described above and cultured in 96-well plates for 24 h. Then, serial dilutions of docetaxel were added. Two days later, 20 μl MTT (Sigma, Germany) was added into each well at 5 mg/ml final concentration for 4 h. After removal of the culture medium, 150 μl DMSO was added for 20 min. The absorbance at 550 nm was detected by CliniBio 128 (ASYS-Hitech, Austria), and the IC~50~ was calculated by SPSS 20.0 package.

Co-culture assay {#sec2-6}
----------------

GFP-S cells were cultured with MCF-7/Doc in 1:1 ratio in six-well plates, and the samples of cell mixture were divided into four groups. After cells had attached, the supernatants were removed, and fresh media containing vehicle, DRβ-H, DRβ-H+D/exo, and DRβ-H+RNase D/exo were added for 48 h. Then, total GFP-S number was microscopically recorded (ImagingA1, Carl Zeiss, Germany) in three non-consecutive fields (magnification ×200). After a 24-h exposure to 50 nM docetaxel, floating cells were discarded, and residual GFP-S cells were counted under fluorescence microscope.

To evaluate the effects of DRβ-H on apoptosis, cell mixtures treated for 48 h with vehicle, DRβ-H, DRβ-H+D/exo, and DRβ-H+RNase D/exo were prepared. After 24 h exposure to 50 nM docetaxel, apoptotic rates of GFP-S were evaluated using the Annexin-V-FITC Apoptosis Detection Kit (BD Biosciences, U.S.A.) based on the manufacturer's instructions and then analyzed by flow cytometry (BD FACSCalibur, U.S.A.).

Western blot {#sec2-7}
------------

Exosomes were lysed using the Total Exosome RNA and Protein Isolation Kit (Invitrogen, U.S.A.) in accordance with the manufacturer's instructions, and exosomal proteins were extracted for Western blot. Proteins were electrophoresed through SDS/PAGE gel and transferred to PVDF membranes. CD63 protein level was quantitated using antibody against CD63 (Santa Cruz Biotechnology, U.S.A.). β-actin (Sigma, Germany) was used to normalize for protein loading. Bound proteins were visualized by the ECL Plus Kit (Millipore, U.S.A.) with Image Lab Software (Bio-Rad, U.S.A.).

RNA isolation and PCR analysis {#sec2-8}
------------------------------

Exosomal RNA was isolated using the Total Exosome RNA and Protein Isolation Kit (Invitrogen, U.S.A.) in accordance with the manufacturer's protocols. In selected experiment, cellular RNA was extracted using the mirVana RNA Isolation Kit (Ambion, U.S.A.) in accordance with the manufacturer's protocols after a 48-h incubation with D/exo, S/exo, and vehicle in six-well plates. Expressions of *Sprouty2, p27*, and *MMP-2* were evaluated. The real-time PCR was performed using SYBR green technique. Briefly, cDNA for miRNA was synthesized using the BU-Script RT Kit (Biouniquer Technology, Nanjing, China) on an iCycler iQ system (Bio-Rad, U.S.A.), and specific stem-loop primers (Springen Biotechnology, Nanjing, China) were designed for the selected miRNAs. All reactions, including the no-template controls, were run in triplicate on a Light Cycler 480 (Roche, Australia). The relative miRNA expressions were calculated using ΔΔ*C*~t~ method and normalized to *U6*.

Evaluation of miRNA transfer {#sec2-9}
----------------------------

GFP-S cells seeded in six-well plates were harvested after 4, 12, and 24 h incubation with evenly divided D/exo or without D/exo as control. Then, cellular RNA from GFP-S was extracted, and PCR was performed as described above. As an indirect measure of miRNA transfer, difference in *C*~t~ values between D/exo-treated GFP-S, and negative control at each time point were determined; positive values indicated miRNA transfer.

Gene target prediction {#sec2-10}
----------------------

The software PicTar (<http://pictar.mdc-berlin.de/>), MicroCosm (<http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/>), and miRDB (<http://www.mirdb.org/miRDB/>) were applied to predict gene targets of selected miRNAs \[[@B18]\]. Only the genes listed by all these three independent tools were considered and searched for gene ontology (GO) term enrichment (<http://www.geneontology.org>) \[[@B21]\]. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed using the DAVID program (<http://david.abcc.ncifcrf.gov/>) \[[@B22],[@B23]\].

Statistical analysis {#sec2-11}
--------------------

Data were analyzed using the SPSS 20.0 package, and graphs were generated by the GraphPad software. All experiments were performed in triplicate. Differences were determined by Student's *t* test or by ANOVA, and *P*\<0.05 was considered statistically significant.

Results {#sec3}
=======

Exosome identification {#sec3-1}
----------------------

After successful isolation of exosomes from the supernatants from MCF-7/Doc and MCF-7/S cells, we observed their morphology and size by TEM. D/exo and S/exo were homogeneous in appearance ([Figure 1](#F1){ref-type="fig"}A,B), ranging from 50 to 100 nm in diameter, with a spheroid shape ([Figure 1](#F1){ref-type="fig"}C). Besides, exosome quantities were similar ([Figure 1](#F1){ref-type="fig"}D).

![Exosome identification\
(**A**) Representative image of TEM of D/exo showing a spheroid shape (scale bar = 200 nm). (**B**) Representative image of TEM of S/exo showing a spheroid shape (scale bar = 200 nm). (**C**) D/exo and S/exo displayed a size ranging from 50 to 100 nm in diameter. (**D**) Exosome protein analysis indicated similar yield of D/exo and S/exo. Data are expressed as mean ± S.D., *n*=3.](bsr-38-bsr20180110-g1){#F1}

D/exo transmit chemoresistance related to miRNAs {#sec3-2}
------------------------------------------------

To better visualize the uptake, GFP-S cells were employed and co-cultured with PKH26-labeled D/exo for 24 h, after which the absorption of exosomes by target cells was observed under a confocal microscope. At low magnification, we found that nearly all the GFP-S contained D/exo with red fluorescence ([Figure 2](#F2){ref-type="fig"}A(a)). At high magnification, after merging green signals from two GFP cells ([Figure 2](#F2){ref-type="fig"}A(b)) and red signals from stained D/exo ([Figure 2](#F2){ref-type="fig"}A(c)), the incorporation and internalization of D/exo were indicated by several engulfed and diffused signals (arrows) on the cell membranes and inside cytoplasm ([Figure 2](#F2){ref-type="fig"}A(d)). Consistent with D/exo uptake, we showed by comparing the variations in *C*~t~ values of miRNAs found in GFP-S alone with those of GFP-S incubated with D/exo that the abundance of several miRNAs (*miR-23a, miR-24*, and *miR-26a*) increased gradually ([Figure 2](#F2){ref-type="fig"}B). Besides, D/exo treatment reduced mRNAs in GFP-S such as *Sprouty2, p27*, and *MMP-2*, known to be respectively targetted by the above miRNAs ([Figure 2](#F2){ref-type="fig"}C).

![D/exo transmit chemoresistance\
(**A**) Confocal laser microscopy indicated successful uptake of D/exo by target GFP-S cells with which they were co-cultured. This image plate illustrates (a) absorption of PKH26-labeled D/exo by almost all the GFP-S at low magnification; (b) green fluorescence from GFP-S at high magnification; (c) PKH26 (red) staining of D/exo at high magnification; and (d) merge image at high magnification showing the incorporation and internalization of D/exo (arrows) on the cell membranes and inside cytoplasm of GFP-S. (**B**) GFP-S cells were incubated with D/exo for 4, 12, and 24 h, and transfer of miRNAs were analyzed by PCR. Time point 0 stands for GFP-S without D/exo. The difference in *C*~t~ values between the negative control (GFP-S alone) and D/exo-treated GFP-S is shown for each miRNA. Positive values indicate miRNA transfer. Data are expressed as mean ± S.D., *n*=3. (**C**) Relative expression of mRNAs in GFP-S was analyzed by PCR. Data are expressed as mean ± S.D., *n*=3, \**P*\<0.05, +D/exo compared with +S/exo. (**D**) Evaluation of MCF-7/Doc incubated with D/exo, and MCF-7/S incubated with vehicle, S/exo, and D/exo for 72 h. Apoptotic rates of MCF-7/S and MCF-7/Doc were then determined after 24 h exposure to 50 nM docetaxel. Data are expressed as mean, *n*=3: \**P*\<0.05, MCF-7/S+D/exo compared with MCF-7/S+S/exo. \*\**P*\<0.05, MCF-7/S+D/exo compared with MCF-7/S+vehicle. (**E**) Representative scatter figures of apoptosis assay by flow cytometry. (**F**) Evaluation of MCF-7/Doc incubated with D/exo, and MCF-7/S incubated with vehicle, S/exo, and D/exo for 72 h. IC~50~ of docetaxel in MCF-7/S and MCF-7/Doc were then determined by MTT assay. Data are expressed as mean ± S.D., *n*=3: \**P*\<0.05, MCF-7/S+D/exo compared with MCF-7/S+S/exo. \*\**P*\<0.05, MCF-7/S+D/exo compared with MCF-7/S+vehicle.](bsr-38-bsr20180110-g2){#F2}

To verify the potential of D/exo in resistance transmission, D/exo were collected and added into MCF-7/S cells. As expected, the apoptotic rate induced by 50 nM docetaxel was relatively high in MCF-7/S treated with vehicle. Incubation of MCF-7/S cells with D/exo decreased apoptotic rate, as compared with control cells treated with S/exo or vehicle, suggesting that D/exo induced apoptosis resistance ([Figure 2](#F2){ref-type="fig"}D,E). Consistent with the data from apoptosis assay, we observed that IC~50~ of MCF-7/S treated with D/exo was higher with respect to control MCF-7/S incubated with S/exo or vehicle ([Figure 2](#F2){ref-type="fig"}F). These results reinforced the significant role of D/exo and contained miRNAs in transferring chemoresistance to recipient cells.

DRβ-H reduces exosome release {#sec3-3}
-----------------------------

Our previous work reported the pro-apoptotic effects of DRβ-H on breast cancer cells and its comprehensive pathways \[[@B13]\]. Therefore, we wondered whether exosome secretion is involved in DRβ-H-mediated growth inhibition. We treated MCF-7/Doc cells with different concentrations of DRβ-H and found that D/exo secretion was decreased after DRβ-H treatment in a dose-dependent manner ([Figure 3](#F3){ref-type="fig"}A). Besides, treatment with high concentration of DRβ-H significantly reduced exosomal marker CD63 with respect to control cells added with lower concentration of DRβ-H, further indicating that DRβ-H could inhibit D/exo release from MCF-7/Doc cells ([Figure 3](#F3){ref-type="fig"}B).

![DRβ-H reduces exosome release\
(**A**) Exosome quantity of MCF-7/Doc treated by different concentrations of DRβ-H (0, 5, 10, 20, 40, and 80 μg/ml). Data are expressed as mean ± S.D., *n*=3. (**B**) Expression of exosomal marker CD63 in D/exo after MCF-7/Doc cells was treated by different concentrations of DRβ-H (0, 20, 40, and 80 μg/ml).](bsr-38-bsr20180110-g3){#F3}

DRβ-H reverses chemoresistance related to exosomes {#sec3-4}
--------------------------------------------------

We previously focussed on the function of exosomes moving from donor drug-resistant cells to recipient sensitive cells and confirmed the significance of D/exo from MCF-7/Doc as mediators to spread resistance capacity \[[@B9]\]. Here, we evaluated the role of exosomes in DRβ-H-mediated resistance reversal. As in our earlier publication, GFP-S cells were maintained with MCF-7/Doc at equal proportion under four conditions: (i) with vehicle, (ii) with DRβ-H, (iii) with DRβ-H+D/exo, and (iv) with DRβ-H+RNase D/exo, after which survival number and apoptotic rate of GFP-S were assessed in the presence of 50 nM docetaxel. Interestingly, incubation of cell mixture with DRβ-H resulted in significantly less surviving GFP-S after docetaxel exposure, as compared with those incubated with vehicle. Moreover, treatment of cell mixture with DRβ-H+D/exo increased GFP-S number with respect to control cells treated with DRβ-H only ([Figure 4](#F4){ref-type="fig"}A,B). Likewise, the apoptotic rate was relatively high in cell mixture added with vehicle, whereas a marked increase in apoptotic rate was found in cell mixture added with DRβ-H. Treatment of cell mixture with DRβ-H+D/exo reduced apoptotic rate with respect to control cells treated with DRβ-H only ([Figure 4](#F4){ref-type="fig"}C). These data collectively suggested that DRβ-H could reverse chemoresistance and that such effect could be partly attributed to D/exo.

![DRβ-H reverses chemoresistance related to exosomes\
Evaluation of GFP-S treated with or without 50 nM docetaxel after cell mixture was cultured with vehicle, DRβ-H, DRβ-H+D/exo, and DRβ-H+RNase D/exo. (**A**) Representative images showing the residual GFP-S cells treated under different conditions. (**B**) Quantitative evaluation of residual GFP-S. Data are expressed as mean ± S.D., *n*=3: \**P*\<0.05, +DRβ-H compared with +vehicle. \*\**P*\<0.05, +DRβ-H+D/exo compared with +DRβ-H. ^\#^*P*\<0.05, +DRβ-H+RNase D/exo compared with +DRβ-H+D/exo. (**C**) Apoptotic rate of residual GFP-S. Data are expressed as mean ± S.D., *n*=3: \**P*\<0.05, +DRβ-H compared with +vehicle. \*\**P*\<0.05, +DRβ-H+D/exo compared with +DRβ-H. ^\#^*P*\<0.05, +DRβ-H+RNase D/exo compared with +DRβ-H+D/exo.](bsr-38-bsr20180110-g4){#F4}

RNase pretreatment of D/exo (referred to as RNase D/exo) significantly reduced surviving GFP-S cells and conferred apoptosis resistance, with respect to D/exo, reinforced the role of RNA molecules loaded by D/exo ([Figure 4](#F4){ref-type="fig"}A--C).

DRβ-H regulates exosomal miRNA expression {#sec3-5}
-----------------------------------------

We recently analyzed the miRNA profiles of D/exo and MCF-7/Doc by microarray and demonstrated that the top 20 most abundant miRNAs transported by D/exo ([Table 1](#T1){ref-type="table"}) were involved in signaling pathways related to therapy failure \[[@B9]\]. To test the hypothesis that DRβ-H could regulate exosomal miRNA expression, we picked five miRNAs (*miR-16, miR-23a, miR-24, miR-26a*, and *miR-27a*) from the top 20 exosomal miRNAs and checked their levels after cells were exposed to DRβ-H. In particular, the treatment of MCF-7/Doc with DRβ-H resulted in less expression of all the selected miRNAs in the corresponding D/exo, as compared with those expressed in original D/exo ([Figure 5](#F5){ref-type="fig"}).

###### The top 20 most abundant miRNAs transported by D/exo

  miRNA ID         Log~2~ (fold change)\*   miRNA ID         Log~2~ (fold change)
  ---------------- ------------------------ ---------------- ----------------------
  hsa-*miR-23a*    9.88                     hsa-*miR-15b*    5.96
  hsa-*miR-1246*   9.60                     hsa-*miR-1290*   5.72
  hsa-let-7b       9.01                     hsa-*miR-31*     5.70
  hsa-let-7a       8.50                     hsa-*miR-92a*    5.25
  hsa-*miR-16*     8.13                     hsa-*miR-191*    5.16
  hsa-let-7c       8.04                     hsa-*miR-30c*    4.62
  hsa-*miR-23b*    7.72                     hsa-*miR-182*    4.31
  hsa-*miR-27a*    7.39                     hsa-*miR-3188*   4.20
  hsa-*miR-103a*   6.83                     hsa-*miR-425*    3.60
  hsa-*miR-26a*    6.58                     hsa-*miR-24*     3.06

\*Fold change = (D/exo)/(S/exo)

![DRβ-H regulates exosomal miRNA expression\
Relative expressions of selected exosomal miRNAs in D/exo after MCF-7/Doc were treated with or without DRβ-H. Data are expressed as mean ± S.D., *n*=3: \**P*\<0.05, DRβ-H treated compared with control.](bsr-38-bsr20180110-g5){#F5}

To understand the biological processes influenced by the upstream differentially expressed miRNAs, we predicted their targets by three independent algorithms, PicTar, MicroCosm, and miRDB. Only the genes listed by all these tools were taken into account. We totally detected 293 putative genes and then performed a GO enrichment analysis using DAVID programme. As listed in [Table 2](#T2){ref-type="table"}, we found a strong over-representation of terms belonging to crucial biological processes. According to KEGG analysis, the candidate genes were suggested to participate in several signaling pathways such as cell cycle, Wnt signaling pathway, focal adhesion, and mRNA surveillance pathway ([Table 3](#T3){ref-type="table"}).

###### GO term analysis with DAVID tool

  GO ID        GO term                                 Gene count   \%     *P*-value
  ------------ --------------------------------------- ------------ ------ -----------
  GO:0005654   Nucleoplasm                             67           24.0   5.0E-5
  GO:0005737   Cytoplasm                               107          38.4   1.0E-4
  GO:0043235   Receptor complex                        10           3.6    1.2E-4
  GO:0005829   Cytosol                                 73           26.2   3.4E-4
  GO:0005634   Nucleus                                 106          38.0   7.2E-4
  GO:0043231   Membrane-bounded organelle              18           6.5    4.1E-3
  GO:1990909   Wnt signalosome                         3            1.1    1.1E-2
  GO:0031672   A band                                  3            1.1    1.8E-2
  GO:0030877   β-catenin destruction complex           3            1.1    1.8E-2
  GO:0005874   Microtubule                             11           3.9    1.8E-2
  GO:0005769   Early endosome                          9            3.2    2.1E-2
  GO:0048471   Perinuclear region of cytoplasm         17           6.1    2.3E-2
  GO:0016581   NuRD complex                            3            1.1    2.9E-2
  GO:0000785   Chromatin                               5            1.8    4.3E-2
  GO:0034673   Inhibin--β-glycan--ActRII complex       2            0.7    4.4E-2
  GO:0036464   Cytoplasmic ribonucleoprotein granule   3            1.1    5.2E-2
  GO:1990851   Wnt--Frizzled--LRP5/6 complex           2            0.7    5.8E-2
  GO:0005730   Nucleolus                               19           6.8    8.7E-2
  GO:0072357   PTW/PP1 phosphatase complex             2            0.7    9.9E-2

###### KEGG pathway analysis with DAVID tool

  Pathway ID   Pathway term                     Genes                                                                      \%    *P*-value
  ------------ -------------------------------- -------------------------------------------------------------------------- ----- -----------
  has04510     Focal adhesion                   *CRKL, RAP1A, COL1A2, COL11A2, GSK3B, PPP1CB, PPP1R12A, RELN, VAV1, ZYX*   3.6   1.0E-2
  has03015     mRNA surveillance pathway        *GSPT1, PYM1, NXF1, NXT2, PPP1CB, PPP2R5E*                                 2.2   2.2E-2
  has04310     Wnt signaling pathway            *LRP5, LRP6, WNT7A, CTNNBIP1, GSK3B, NFATC3, SIAH1*                        2.5   3.5E-2
  has04931     Insulin resistance               *GFPT2, GSK3B, INSR, PRKCD, PPP1CB, RPS6KA6*                               2.2   4.2E-2
  has04722     Neurotrophin signaling pathway   *CRKL, RAP1A, BEX3, GSK3B, PRKCD, RPS6KA6*                                 2.2   6.1E-2
  has04110     Cell cycle                       *WEE1, CHEK1, CCNE1, CCNH, GSK3B, YWHAQ*                                   2.2   6.8E-2

Discussion {#sec4}
==========

Docetaxel-based chemotherapy plays a vital role against breast cancer, but the efficacy is mainly restricted by drug resistance. Previously, we reported that DRβ-H, a novel component obtained from natural plant *C. ganpiniana*, exerts strong inhibitory activity on different breast cancer cells and may be a potential option for drug development and tumor treatment \[[@B12]\]. In the present work, we first report that DRβ-H could suppress breast cancer growth by regulating intercellular resistance transmission via reducing exosome release.

The emerging evidence that cells may communicate with surrounding cancer cells or stromal cells within tumor microenvironment through the secretion of exosomes carrying genetic information has recently highlighted the importance of these entities \[[@B2],[@B3],[@B10],[@B24]\]. In the present study, D/exo from MCF-7/Doc could be absorbed by recipient breast cancer cells, and are effective in transferring chemoresistance from drug-resistant cells to sensitive ones. This was based on the confocal microscopic visualization of red-labeled D/exo on the cell membranes and inside cytoplasm of GFP-S and further verified by analyzing the apoptosis and MTT assay. We also confirmed that miRNAs delivered by D/exo were functional because able to reduce the target gene expressions. A similar pattern was found in prostate cancer cells to docetaxel and lung cancer cells to cisplatin, reinforcing the potential of tumor-derived exosomes in resistance transmission \[[@B6],[@B25]\].

Recently, the anticancer effects of DRβ-H have attracted much attention. Our previous study provided apoptotic activity and the mechanism for the anticancer capacity of DRβ-H \[[@B13]\]; however, the relevance of exosomes during DRβ-H exposure has yet to be determined. In the present study, D/exo yield was decreased after DRβ-H treatment in a dose-dependent manner, and exosomal marker CD63 was negatively correlated with DRβ-H concentration, indicating that DRβ-H could influence D/exo release from MCF-7/Doc cells. Several mechanisms have been suggested to control the biogenesis and shedding of exosomes \[[@B24]\]. Although the underlying molecular machinery remains largely unclear, it seems plausible that reducing the formation and secretion of exosomes may be a novel therapeutic strategy \[[@B10],[@B11]\]. Besides, many specific exosomal markers including CD63 could be found in the popular exosome database Exocarta (<http://www.exocarta.org>), offering more methods for exosome detection \[[@B26]\].

Limited studies, to date, have demonstrated that exosomes were involved in reversing drug insensitivity, we therefore evaluated the role of exosomes in DRβ-H-mediated resistance reversal. Interestingly we found reduced docetaxel resistance in cell mixture in the presence of DRβ-H, compared with when these cells were treated with vehicle. In keeping with the findings from our initial exosome co-culture assay, we observed a similar trend of conferred docetaxel resistance to cell mixture in the presence of DRβ-H and D/exo, with respect to cell mixture treated with DRβ-H only. These indicated that DRβ-H could reverse chemoresistance and that such effect could be partly attributed to D/exo. Thus, it is speculated that drug-resistant breast cancer cells could spread resistance traits to residual sensitive cells via exosomes after toxic insult, whereas DRβ-H blocks resistance transmission by reducing exosomes from drug-resistant cells. We have not tested the efficacy of DRβ-H and D/exo in reversing drug sensitivity, further investigations are needed to more precisely elucidate the relevance.

Remarkably, an explanation for the manner whereby D/exo restored docetaxel resistance of cell mixture in the presence of DRβ-H is that they are transferring miRNAs from MCF-7/Doc that are causal molecules in changing the susceptibility of co-cultured GFP-S. Our study suggests that the miRNA content of D/exo plays an important role, as the RNase treatment of D/exo significantly abrogated the biological effects of D/exo. Although we have not applied the miRNA microarray method to detect all the differentially expressed exosomal miRNAs after DRβ-H treatment, we showed that DRβ-H influenced the expressions of all the selected exosomal miRNAs. Based on target prediction and pathway analysis, these miRNAs were suggested to participate in pathways related to treatment failure, such as cell cycle, Wnt signaling pathway, focal adhesion, and mRNA surveillance pathway \[[@B27],[@B28]\]. This is in keeping with our previous publication that the top 20 most abundant miRNAs transported by D/exo take part in signaling pathways related to therapy failure \[[@B9]\].

In conclusion, the results of the present study expand on previous findings and provide the first evidence suggesting that, in breast cancer, DRβ-H acts through reducing the secretion of exosomes from drug resistant cells and that this mechanism may be responsible for DRβ-H-mediated resistance reversal. This would offer new insights into design new strategy for overcoming exosome-associated resistance transmission.
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DRβ-H

:   [d]{.smallcaps}rhamnose β-hederin

GFP-S

:   MCF-7/S expressing GFP

GO

:   gene ontology

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

MCF-7/Doc

:   docetaxel-resistant breast cancer cell MCF-7
